Introduction
Even with autologous stem cell transplantation, the rate of long-term survival of myeloma is currently only 35-40% [1] . Median survival time is 4 to 5 years [2] [3] [4] . The relapse rate is high and relapsed myeloma is particularly resistant to conventional chemotherapy.
Proteasome inhibitors are a new class of drugs that are particularly effective in myeloma compared with most other cancers. Bortezomib is the first approved for clinical use. In phase II/III clinical trials, 35-50% of relapsed and refractory myelomas were sensitive to bortezomib [5] [6] [7] [8] . The peculiar sensitivity of myeloma to the drug is not well understood, but the Unfolded protein Response (UPR) is a convincing target [9] . Bortezomib is a specific and reversible inhibitor of chymotryptic activity of the 26S proteasome, the major cellular pathway of protein degradation and, as a consequence, its biological effects are numerous.
Attention on its anticancer action has focused on NF-κB, p53, cyclin-dependent kinase inhibitors p21 and p27, apoptotic pathways, growth factor signalling, the interaction of myeloma cells and bone marrow stroma, angiogenesis, and stress responses [10] [11] [12] [13] [14] .
However, none of these effects has so far proved related to drug response and the relevant mechanism by which bortezomb kills myeloma cells has remained elusive. Similarly, the causes of primary and acquired resistance to the drug are unknown.
Plasma cells, the normal counterparts of myeloma, are specialized, terminally differentiated secretory B lymphocytes capable of prodigious antigen-specific immunoglobulin production. The UPR is essential for the folding of both heavy and light immunoglobulin chains and their assembly [15] [16] [17] . The UPR is also required for disposal of irreversibly misfolded polypeptides via the ubiquitin-proteasome pathway [18] . Proteasome inhibition increases the accumulation of misfolded proteins and hence invokes the UPR at the same time as disrupting it. The possibility thus arises that dependence on the UPR renders myeloma sensitive to proteasome inhibitors. There is some in vitro evidence that sensitivity of myeloma cell lines to bortezomib is related to high level immunoglobulin production [9] , although serum immunoglobulin levels have not predicted response in clinical trials.
The transcription factor XBP-1 is a major regulator of the UPR that is expressed at high levels in myelomas compared with other cancers and is indispensable for plasma cell development [19] [20] [21] [22] . Xbp-1-deficient mice lack plasma cells and have impaired immunoglobulin production [21] . Myeloma cell lines in which XBP-1 expression was knocked down had higher apoptotic indices and reduced survival [23] . Active XBP-1 is generated by unconventional extra-nuclear splicing of its mRNA by endoribonuclease IRE1, in response to exposed hydrophobic moieties on misfolded or unfolded proteins in the endoplasmic reticulum (ER). Spliced XBP-1 mRNA encodes an active transcription factor for downstream stress response genes including ERDJ3, ERDj4, p58 IPK , EDEM, HEDJ, EDEM, RAMP4 and protein disulfide isomerase-P5 [24, 25] . Unspliced XBP-1 6 mRNA encodes an inactive or dominant negative protein lacking the transactivation domain.
In this study, we relate XBP-1 expression to primary sensitivity or resistance of myeloma to bortezomib both in vitro and in patients, and with acquired resistance to bortezomib in vitro.
Acquired resistance is associated with downregulation of XBP-1 and ATF6 and reduction in immunoglobulin secretion. These results point to the Unfolded Protein Response as the relevant target pathway of bortezomib in myeloma cells. XBP-1 or other components of the UPR might be used clinically as predictors of response to bortezomib.
DESIGN AND METHODS

XBP-1 assays
Spliced and unspliced XBP-1 mRNA differ by a 26-bp intron homologous to adjacent sequences, complicating the use of specific primers or Taqman probes to distinguish the two forms directly. Hence, total XBP-1 cDNA was amplified with primers spanning the intron; relative abundance of the two forms of the mRNA was determined by quantification of the respective PCR products.
Total RNA was extracted from myeloma cells using isophasic guanidine isothiocyanate:phenol (Tri Reagent, MRC) and treated with DNase I (Ambion 
Cytotoxicity Assays
Cytotoxicity assays for non-myeloma cell lines were performed essentially as described [27] ; modifications were made to allow for the slow growth, non-adherence and dilution- FACSAria. The fixed sample was used to verify correct gating of the myeloma populationbrightest for CD38 and cytoplasmic light chain. The corresponding live cell population gated was CD38 bright, CD14 -ve (to exclude non-myeloma monocytic cells) and DAPIve. Yields were 5,000-500,000 cells, which were stored at -70˚C until RNA extraction.
SDS-PAGE and immunoblot analysis
Cells were lysed by 3 freeze-thaw cycles in 0.1% Triton-X 100, 10 mM Tris HCl pH 8.0, 10 mM MgCl 2 , 2 mM CaCl 2 and protease inhibitor cocktail (Sigma). The lysate was clarified by centrifugation at 14,000 g at 4˚C. Protein was quantified by Bradford assay (BioRad).
Lysates 
Immunoglobulin secretion
Cells were seeded at 10 6 /ml in complete medium. After 24 hr, the culture supernatant was clarified by centifugation. Secreted immunoglobulin therein was assayed by sandwich ELISA, essentially as described [28] . Capture antisera (SouthernBiotech) were goat F(abʼ)2 anti-human IgG or goat F(abʼ)2 anti-human IgL kappa, both 1:1000. Detection antisera were biotinylated versions of the capture antisera. Standards were purified human IgG (Sigma, I8640), a dilution series in 1% BSA in PBS.
Proteasome activity
Proteasome chymotryptic activity was assayed by cleavage of a pro-luminescent peptideluciferin substrate -Proteasome Glo (Promega), per manufacturers directions.
Luminescence was measured on a Wallach Victor plate reader.
Over-expression and knockdown of XBP-1
Unspliced and spliced XBP-1 cDNAs were cloned based on the sequence of 
Statistical analysis
The distribution of XBP-1 levels was heavily skewed so hypothesis testing was performed on logarithms of the raw data, using unpaired t-tests, two tailed. The spread of the data was less for the cell lines so Spearmanʼs non-parametric R was used to quantify correlations. Analyses were performed with Graphpad Prism 4. Total XBP-1 mRNA levels showed a strong inverse correlation with the IC50s for bortezomib (Spearmanʼs r = -0.89; Figure 1A) i.e. high levels of XBP-1 were associated with sensitivity to the drug. Unspliced XBP-1 levels showed a similar relationship ( Figure   1B ), as it was the dominant form of the transcript in the myeloma cell lines tested and, indeed, most other tumour cell lines tested (supplementary data, Figure S1 ). Spliced XBP-1 mRNA was the minority species and its correlation with bortezomib sensitivity was weaker (r = -0.60; Figure 1C ), due to an outlier. Although the ratio of spliced:unspliced XBP-1 mRNA might also indicate the degree activation of the UPR, it was not related to bortezomib sensitivity ( Figure 1D ).
RESULTS
Sensitivity
14
The relationship between XBP-1 mRNA levels and sensitivity to bortezomib was much weaker in a panel of non-myeloma human lymphoid cell lines (Methods), including Burkitt lymphomas, T lymphoblastoid lines, one lymphoplasmacytoid line and a panel of solid tumour cell lines including neuroblastoma, lung cancer, colon cancer, ovarian, cervical cancer and prostate cancers ( Figure 1E ). It may be noted however that the levels of XBP-1 mRNA in the non-myeloma cell lines were often much lower than in the myelomas, which again suggests that high XBP-1 levels are indicative of sensitivity to bortezomib.
Other components of the UPR were examined by immunoblots. It is interesting that ATF6 levels were also higher in bortezomib-sensitive myeloma cell lines ( Figure 1F ) whereas neither BiP, the main molecular chaperone in the endoplasmic reticulum, nor phosphorylated eIF2a, were related to sensitivity. ATF6 is a regulator of the UPR with functions similar to XBP-1.
XBP-1 levels correlate with response of clinical myelomas to bortezomib
A retrospective pilot study was conducted of 17 relapsed or refractory myeloma patients treated with bortezomib alone or in combination with corticosteroid. Patient characteristics are described in Table 1 An independent analysis was performed on a second cohort of myeloma patients from Victoria, Australia. A similar trend was evident, albeit weaker ( Figure 2E ). This cohort consisted of banked marrow biopsies obtained from more diverse sources and included a higher proportion of patients (21/25) treated with corticosteroids (some high-dose) concurrently with bortezomib, which partially accounts for the presence of responders with low XBP-1 levels.
Downregulation of XBP-1, ATF6 and immunoglobulin synthesis in bortezomibresistant myeloma cell lines
Bortezomib-resistant sublines of the KMS-11 myeloma cell line were derived by long-term adaptation to continuous exposure to increasing concentrations of bortezomib, ultimately 3-4 fold times the starting IC50. These resistant sub-lines showed no loss of sensitivity of the proteasome itself to bortezomib, as indicated by inhibition of proteolysis of a fluorescent substrate probe ( Figure 3A) . Thus the resistance could not be due to mutation of the proteasome. However, in multiple independently derived resistant sub-lines, total XBP-1 mRNA levels were substantially reduced compared with the bortezomib-sensitive parent cell line KMS-11 ( Figure 3B) ; the greater the resistance to bortezomib, the greater was the reduction in XBP-1 levels. This reduction was not a short-term artefact of exposure to bortezomib as it persisted for at least 48 h after bortezomib was washed off. The downregulation of total XBP-1 mRNA in bortezomib-resistant myeloma lines was accompanied by a reduction in the proportion of the spliced form of the transcript ( Figure   3C ), which encodes the active XBP-1 protein. Together, these results suggest a marked suppression of elements of the UPR accompanying acquisition of resistance to bortezomib.
Immunoblot analysis of other UPR components ( Figure 3D ) indicated that resistant sublines also had reduced expression of transcription factor ATF6, which is responsible for activation of chaperones in the UPR, a similar function to XBP-1. The expression of phosphorylated-eIF2α was consistently upregulated in the bortezomib-resistant sub-lines ( Figure 3D ), suggesting overall downregulation of protein synthesis.
Indeed, immunoglobulin production was suppressed in the bortezomib resistant myeloma sub-lines, as determined by ELISA ( Figure 3E (Table 2) , as predicted.
Modulation of XBP-1 levels has little effect on sensitivity to bortezomib
XBP-1 mRNA levels in H929 and RPMI-8226 cells were knocked down by ectopic expression of shRNAs in lentiviral vectors. H929 cells had high starting levels of XBP-1 and the knockdown resulted in decreased sensitivity to bortezomib but the result was not statistically significant ( Figure 4A ). RPMI-8226 cells had a low initial level of XBP-1 and knockdown to even lower levels had no effect on sensitivity to Bortezomib.
The consequences of over-expressing either the spliced or unspliced form of XBP-1 were also investigated in RPMI-8226 cells, chosen for their low levels of the endogenous mRNA.
High-level over-expression of each form was achieved ( Figure 4B ). However, transfectants of unspliced XBP-1 also showed marked elevation of spliced XBP-1, likely because there was a larger pool available for splicing by IRE-1. Similarly, when spliced XBP-1 was overexpressed, the levels of the unspliced form also increased. The transcription factor derived from the spliced form of XBP-1 has been shown to act on its own promoter, thus increasing transcription of the unspliced mRNA [23] . Thus, despite altering the ratio of unspliced:spliced mRNA, the net effect on the relative influence of active vs.
inactive/dominant negative XBP-1 proteins was uncertain. Both manipulations sensitised RPMI-8226 cells to bortezomib, but the changes were modest and statistically significant only for transfectants of the spliced form ( Figure 4C ).
DISCUSSION
Proteasome inhibitors and other new drugs are revolutionising the treatment of myeloma.
When the choice of several agents is available, markers associated with drug response provide the opportunity for optimising combination chemotherapy for individual patients, avoiding needless side effects, and time and expense lost to suboptimal regimens.
Response markers highlight the relevant biological pathways affected by a drug and the changes which mediate drug resistance, thus pointing the way to better drugs and new drug targets. Other cancers with an active UPR, such as prostate, breast and pancreas are also relatively sensitive to bortezomib. The original screen of the NCI tumour cell line panel identified prostate cancer as particularly sensitive [39] and it is interesting that although only three prostate cell lines were examined in this study, the relationship between XBP-1 and bortezomib sensitivity held for that small group ( Figure 1E ). Bortezomib is also an effective treatment for mantle cell lymphoma [40] and Waldenstrom's macrogobulinaemia [41] . While the reason for the sensitivity of mantle cell lymphoma to bortezomib is unknown, it is similar to myeloma in having a mature B cell immunophenotype and strong expression of immunoglobulins, in this case surface Ig. It would thus be of interest to test whether XBP-1 levels are significantly related to response in the context of clinical trials of bortezomib for cancers other than myeloma.
It is particularly interesting that resistance to bortezomib was accompanied by increased sensitivity to three other drugs. Thus, multidrug sensitivity, rather than multidrug resistance, may follow bortezomib treatment. If that is indeed the case it has important implications for the order in which bortezomib is employed vis. other treatment options. It might also explain, in part, the high response rates obtained by combining cytotoxic drugs with bortezomib [35, 36] .
The changes in sensitivity to bortezomib that followed manipulation of XBP-1 levels by overexpression or knockdown were in line with the correlation observed in other contexts.
Even so, the modest scale of those effects suggests that XBP-1 does not determine sensitivity to proteasome inhibitors directly but is, rather, a surrogate marker of sensitivity.
XBP-1 is a major regulator of the UPR so its normal level may reflect a corresponding degree of cellular dependence on the UPR. Changing XBP-1 mRNA levels need not affect that dependence strongly. This interpretation remains subject to the caveat that levels of the spliced and unspliced forms of XBP-1 could not be altered independently and the net effect was thus uncertain.
In summary, in the context of myeloma, high XBP-1 mRNA levels appear to be associated with sensitivity to bortezomib and low levels with resistance. XBP-1 levels constitute a potential bortezomib response marker, whose clinical utility needs to be confirmed in larger, controlled patient studies. Its value for predicting response to combination therapy or cross-resistance to other drugs also warrants investigation. The view that myeloma is inherently sensitive to proteasome inhibitors because of its dependence on the UPR is satisfying, being consistent with the known high levels of XBP-1 in plasma cells, myeloma and myeloma cell lines, the particular sensitivity of myeloma to the drugs, and the new observations presented herein. This model suggests that elements of the UPR may be appropriate targets for new drugs for myeloma and also that drugs that induce the UPR will sensitise cells to proteasome inhibitors. 
